Biotech Stock Movers (VICL, BDSI, TNGN, DNDN, REGN)

Vical Incorporated (NASDAQ: VICL) plunged 12.15% to $3.76 in the morning hour after the company announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $3.75 per share. The gross proceeds to us from this offering are expected to be approximately $50 million.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) soared 122.62% to $1.87 on an unusual volume of 2.19 million shares in the morning hour after the company announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP) for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.

Tengion, Inc. (NASDAQ: TNGN) climbed 10.52% to $0.637 in the morning hour after the company announced it has completed the relocation of its corporate headquarters from East Norriton, Pennsylvania to the Company’s existing facility in Winston-Salem, North Carolina.

Dendreon Corporation (NASDAQ: DNDN) gained 7.72% to $11.45 in the morning hour after the company announced revenue for the fourth quarter ended December 31, 2011, reporting gross product revenue of approximately $82 million. This represents approximately 25% growth over the third quarter ended September 30, 2011. In addition, Dendreon reported full-year gross revenues from PROVENGE (sipuleucel-T) sales of approximately $228 million.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) increased 6.18% to $64.74 in the morning hour. The 52 week trading range for the company is $32.32 – $79.90. The company has soared 88% in the last one year. Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions.


The assembled information distributed by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented herein. will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.


Tagged with: | | | |
Our Research Report on VICL is now available. Don´t Trade VICL until you Read our FREE FULL REPORT. Click Here